GSK, GB0009252882

GSK stock heads into the open after a 1.2 percent slide

Published on 09/21/2026 at 03:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 18, 2026, GSK stock finished at GBP 1,877.50 on the London Stock Exchange, down 1.2 percent, with an intraday range between GBP 1,852.50 and GBP 1,912.00. Today, investors watch the impact of a fresh Berenberg upgrade on GSK stock.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht
GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK stock closed at GBP 1,877.50 on the London Stock Exchange on September 18, 2026, losing 1.2% from the prior session. Per London market data, the shares traded between GBP 1,852.50 and GBP 1,912.00 during the day, with volume around 15.7 million shares and the move lagging a broadly stable FTSE 100.

September 18, 2026 in numbers

GSK plc (ISIN GB0009252882, LSE: GSK) ended the last completed London session on September 18, 2026 at GBP 1,877.50, down 22.50 pence or 1.18% on the day, after moving between a low of GBP 1,852.50 and a high of GBP 1,912.00, with reported turnover near 15.67 million shares. According to United Kingdom share tables from a major market portal, this placed the close below the upper end of GSK's recent trading band while the broader FTSE 100 index finished little changed on the same date, so GSK underperformed its home benchmark in that session.

As IT-Boltwise reported on September 20, 2026, Berenberg recently upgraded its view on GSK and lifted its price target to GBP 22, citing confidence in the pipeline and earnings outlook. The same report noted that the shares had shown relative stability around current levels following the recommendation change, suggesting that analyst commentary remains a relevant factor for trading interest even when the stock posts a modest daily decline.

Analyst focus and news flow today

Today, the Berenberg upgrade and the raised GBP 22 price target for GSK, highlighted by IT-Boltwise, remain in focus ahead of the London open as investors assess how renewed analyst support might influence demand for the shares. In addition, recent coverage of GSK's strategic moves in oncology, including a deal reported by This is Money on September 20, 2026 about the company returning to China through a blood cancer drug agreement, adds to the broader news backdrop that may shape sentiment toward GSK stock today.

Disclaimer...

en | GB0009252882 | GSK | boerse | 70140351 | bgmi